Table 2.
Patient characteristics of the four patient groups, representing control group: patients without NET diagnosis based on PET/CT, group 1: primary tumors solely or with a few (≤ 2) metastases (limited disease), group 2: liver-only metastases and group 3: extensive metastases
| Parameters | [68Ga]Ga-DOTATATE | [68Ga]Ga-HA-DOTATATE | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control group (n = 41) | Group 1 (n = 10) | Group 2 (n = 4) | Group 3 (n = 25) | p-value | Control group (n = 45) | Group 1 (n = 21) | Group 2 (n = 7) | Group 3 (n = 31) | p-value | |
| Male | 22 (54%) | 4 (40%) | 2 (50%) | 8 (32%) | < 0.001 | 20 (44%) | 10 (48%) | 3 (43%) | 15 (48%) | < 0.001 |
| Female | 19 (46%) | 6 (60%) | 2 (50%) | 17 (68%) | 25 (56%) | 11 (52%) | 4 (57%) | 16 (52%) | ||
| Age (years) | 56 ± 14 (22–79) | 64 ± 9 (46–75) | 57 ± 12 (48–75) | 62 ± 13 (39–84) | 0.200 | 59 ± 12 (27–84) | 65 ± 9.83 (47–80) | 57 ± 9.81 (44–67) | 61 ± 11.7 (40–82) | 0.282 |
| Weight (kg) | 81.1 ± 18.4 (53–120) | 77.6 ± 14.2 (60–104) | 88.3 ± 13.0 (73–103) | 75.7 ± 15.0 (53–117) | 0.415 | 87.6 ± 22.3 (40–145) | 73.5 ± 16.1 (44–113) | 78.6 ± 18.1 (52–102) | 69.6 ± 10.6 (51–100) | 0.001 |
| Height (cm) | 176 ± 11.3 (155–196) | 169 ± 6.72 (158–180) | 174 ± 9.29 (164–182) | 171 ± 7.94 (157–185) | 0.270 | 173 ± 10.2 (154–193) | 171 ± 8.30 (160–186) | 174 ± 11.3 (159–185) | 174 ± 7.70 (158–192) | 0.871 |
| GFR (Cockcroft Gault, mL/min) | 94.8 ± 31.5 (49.6–160) | 101 ± 31.5 (47.4–146) | 99.6 ± 10.2 (93.4–115) | 85.3 ± 26.5 (33.8–124) | 0.482 | 115 ± 42.5 (41.7–190) | 84.0 ± 21.5 (50.3–117) | 93.0 ± 49.1 (41.3–183) | 79.3 ± 20.4 (35.8–123) | 0.107 |
| Peptide amount administered (µg) | 12.5 ± 2.65 (8.05–16.9) | 13.1 ± 1.45 (10.6–15.7) | 14.5 ± 1.08 (13.4–16.0) | 12.8 ± 2.48 (7.16–16.6) | 0.465 | 6.13 ± 2.29 (2.49–11.2) | 5.22 ± 1.58 (2.43–7.78) | 6.74 ± 2.72 (3.31–11.1) | 6.47 ± 2.44 (3.37–11.0) | 0.204 |
| Radioactivity administered (MBq) | 91.7 ± 23.4 (43.4–130) | 79.7 ± 14.2 (57.8–101) | 83.7 ± 15.3 (64.7–99.6) | 88.5 ± 16.6 (50.3–133) | 0.378 | 89.5 ± 11.4 (66.0–110) | 84.9 ± 14.2 (60.1–106) | 85.8 ± 12.0 (69.0–105) | 86.2 ± 14.8 (43.8–106) | 0.513 |
| Injection-acquisition interval (min) | 48 ± 11 (35–78) | 43 ± 7 (34 -55) | 43 ± 2 (41–45) | 44 ± 6 (35–55) | 0.153 | 45 ± 6 (35–55) | 42 ± 6 (29–55) | 44 ± 7 (35–52) | 45 ± 6 (35–55) | 0.358 |
Continuous variables are shown as mean ± standard deviation (range) and categorical variables as number (%)
GFR Glomerular filtration rate